Nuvectis Pharma Inc — Cash Flow (NASDAQ:NVCT) | MetaTrader

Open full chart

Financials

Overview Отчетность Statistics Dividends

Quarterly Annual

Cash from operating activities 13.56 M15.95 M12.25 M16.01 M 16.01 M Cash from investing activities —000 0 Cash from financing activities 27.81 M15.09 M11.65 M29.11 M 29.11 M Free cash flow 13.56 M15.95 M12.25 M16.01 M 16.01 M

Новости

Nuvectis начинает испытания фазы 1b комбинации NXP900 с осимертинибом

Nuvectis initiates phase 1b trial combining NXP900 with osimertinib

H.C. Wainwright подтверждает рейтинг акций Nuvectis Pharma на уровне "Покупать"

Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright

Каплан покупает акции Nuvectis Pharma (NVCT) на сумму $64 240

Председатель Nuvectis Pharma Бенцур покупает акции на $28 600

Директор Nuvectis Pharma Санчес приобрел акции NVCT на $75 тыс.

H.C. Wainwright подтверждает рейтинг "Покупать" для акций Nuvectis Pharma

H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target

Nuvectis Pharma adds former Intra-Cellular exec to board of directors

Nuvectis initiates phase 1b program for cancer drug NXP900

Nuvectis (NVCT) Q2 Loss Widens 43%